- Home
- VRAX vs CNSP Comparison
VRAX vs CNSP Comparison
Compare VRAX & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRAX | CNSP |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7M | 2.1M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | VRAX | CNSP |
|---|---|---|
| Price | $0.20 | $2.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $1.00 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 178.8K | 29.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $217,274.83 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.18 | $0.73 |
| 52 Week High | $1.35 | $10.59 |
Technical Indicators
Market Signals| Indicator | VRAX | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 42.36 | 26.57 |
| Support Level | $0.20 | $0.77 |
| Resistance Level | $0.25 | $4.00 |
| Average True Range (ATR) | 0.02 | 0.33 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 34.84 | 9.65 |
Price Performance
Historical ComparisonAbout VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.